Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Gnrh Antagonists

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    11 result(s) found for: Gnrh Antagonists. Displaying page 1 of 1.
    EudraCT Number: 2015-005098-19 Sponsor Protocol Number: 1414-ROG-GUCG Start Date*: 2017-09-28
    Sponsor Name:European Organisation for Research and Treatment of Cancer (EORTC)
    Full Title: Phase IIIb randomized trial comparing irradiation plus long term adjuvant androgen deprivation with GnRH antagonist versus GnRH agonist plus flare protection in patients with very high risk localiz...
    Medical condition: very high risk localized or locally advanced prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: BE (Ongoing) ES (Restarted) FR (Ongoing) AT (Completed) DE (Ongoing) GB (GB - no longer in EU/EEA) DK (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-000212-89 Sponsor Protocol Number: antagovo Start Date*: 2008-03-04
    Sponsor Name:Instituto Universitario IVI Valencia
    Full Title: Uso de antagonistas de la GnRH en la preparación endometrial de las receptoras de ovocitos.
    Medical condition: Comparar los resultados obtenidos con el empleo de antagonistas de la GnRH en la sincronización receptora de ovocitos–donante frente a los resultados obtenidos con el tradicional empleo de supresió...
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-003996-23 Sponsor Protocol Number: SAKK08/16 Start Date*: 2017-08-29
    Sponsor Name:SAKK
    Full Title: ODM-201 maintenance therapy in patients with metastatic castration resistant prostate cancer (mCRPC) previously treated with one novel hormonal agent first line and nonprogressive disease after sec...
    Medical condition: Metastatic castration resistant prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10007453 Carcinoma of the prostate metastatic LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Prematurely Ended) ES (Ongoing) FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-002965-39 Sponsor Protocol Number: RHMCAN0890 Start Date*: 2013-04-29
    Sponsor Name:Swiss Group for Clinical Cancer Research (SAKK)
    Full Title: Orteronel maintenance therapy in patients with metastatic castration resistant prostate cancer and non-progressive disease after first-line docetaxel therapy: A multicenter randomized double-blind ...
    Medical condition: Castration Resistant Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062904 Hormone-refractory prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-002814-38 Sponsor Protocol Number: SP005 Start Date*: 2013-09-27
    Sponsor Name:SOTIO a.s.
    Full Title: A Randomized, Double Blind, Multicenter, Parallel-group, Phase III study to evaluate efficacy and safety of DCVAC/PCa versus Placebo in Men with metastatic Castration Resistant Prostate Cancer elig...
    Medical condition: metastatic castrate-resistant prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SE (Completed) GB (Completed) DE (Completed) BE (Completed) CZ (Completed) IT (Completed) NL (Completed) ES (Completed) HU (Completed) PT (Completed) BG (Completed) SK (Completed) PL (Completed) HR (Completed) AT (Completed) LV (Completed) LT (Completed) DK (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2010-023987-41 Sponsor Protocol Number: 2010.2611 Start Date*: 2011-06-24
    Sponsor Name:University Medical Center Groningen
    Full Title: In vivo imaging of the effect of fulvestrant on availability of estrogen receptor binding sites in metastatic breast tumor lesions using [18F]FES-PET
    Medical condition: Estrogen Receptor-positive metastatic breast cancer patients that will be treated with fulvestrant
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-004114-99 Sponsor Protocol Number: FERTIRES-2016 Start Date*: 2017-05-18
    Sponsor Name:AB-BIOTICS
    Full Title: USE OF P.N680S POLYMORPHISM TO CHOOSE THE EXOGEN FSH DOSE IN CONTROLLED OVARIAN HYPERSTIMULATION: A PROSPECTIVE TRIAL
    Medical condition: Infertility
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-005611-46 Sponsor Protocol Number: TAVT45C02 Start Date*: 2021-06-21
    Sponsor Name:Tavanta Therapeutics, Inc.
    Full Title: Phase 3 study investigating the efficacy and safety of TAVT-45 (abiraterone acetate) Granules for Oral Suspension (a novel abiraterone acetate formulation) relative to a reference abiraterone aceta...
    Medical condition: Metastatic Castrate Sensitive Prostate Cancer (mCSPC) and metastatic Castrate Resistant Prostate Cancer (mCRPC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10076506 Castration-resistant prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FR (Completed) SE (Completed) HU (Completed) ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2012-001461-32 Sponsor Protocol Number: OGX-011-12 Start Date*: 2012-07-12
    Sponsor Name:OncoGenex Technologies Inc.
    Full Title: A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination with Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men with Metastatic Castrate Resistant ...
    Medical condition: Metastatic Castrate Resistant Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062904 Hormone-refractory prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Completed) HU (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2015-001361-27 Sponsor Protocol Number: ICR-CTSU/2015/10054 Start Date*: 2016-09-21
    Sponsor Name:The Institute of Cancer Research
    Full Title: CTC-STOP: Utilising Circulating Tumour Cell (CTC) Counts to Optimize Systemic Therapy of Metastatic Prostate Cancer.
    Medical condition: Advanced Castration Resistant Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10001198 Adenocarcinoma of the prostate metastatic LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-000209-10 Sponsor Protocol Number: D8731C00002 Start Date*: 2020-10-20
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase II, Open-label Study to Assess the Efficacy, Safety, and Tolerability of AZD4635 in Combination with Durvalumab and in Combination with Cabazitaxel and Durvalumab in Patients Who Have Progr...
    Medical condition: Progressive Metastatic Castrate-Resistant Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: BE (Completed) DE (Completed) FR (Completed) DK (Completed) NL (Completed) IT (Ongoing)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 01:45:39 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA